Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Antiphospholipid syndrome

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Testicular cancer

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Invasive candidiasis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Bipolar disorders

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Narcolepsy

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Diabetic retinopathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cardiovascular Manifestations of Systemic Sclerosis: A Danish Nationwide Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Functional neuroimaging of recovery from motor conversion disorder: A case report

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care - 2-year outcomes and predictors

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  • Karen Schreiber
  • Savino Sciascia
  • Philip G de Groot
  • Katrien Devreese
  • Soren Jacobsen
  • Guillermo Ruiz-Irastorza
  • Jane E Salmon
  • Yehuda Shoenfeld
  • Ora Shovman
  • Beverley J Hunt
Vis graf over relationer

Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of antiphospholipid antibodies, such as lupus anticoagulant, anticardiolipin antibodies and anti-β2-glycoprotein 1 antibodies. APS can present with a variety of clinical phenotypes, including thrombosis in the veins, arteries and microvasculature as well as obstetrical complications. The pathophysiological hallmark is thrombosis, but other factors such as complement activation might be important. Prevention of thrombotic manifestations associated with APS includes lifestyle changes and, in individuals at high risk, low-dose aspirin. Prevention and treatment of thrombotic events are dependent mainly on the use of vitamin K antagonists. Immunosuppression and anticomplement therapy have been used anecdotally but have not been adequately tested. Pregnancy morbidity includes unexplained recurrent early miscarriage, fetal death and late obstetrical manifestation such as pre-eclampsia, premature birth or fetal growth restriction associated with placental insufficiency. Current treatment to prevent obstetrical morbidity is based on low-dose aspirin and/or low-molecular-weight heparin and has improved pregnancy outcomes to achieve successful live birth in >70% of pregnancies. Although hydroxychloroquine and pravastatin might further improve pregnancy outcomes, prospective clinical trials are required to confirm these findings.

OriginalsprogEngelsk
TidsskriftNature reviews. Disease primers
Vol/bind4
Udgave nummer17103
Sider (fra-til)17103
ISSN2056-676X
DOI
StatusUdgivet - 11 jan. 2018

ID: 56674510